The Price-to-Dream Trap in IPO Valuation: Risks Behind High-Growth Narratives

The Hong Kong Stock Exchange (HKEX) recorded 73 new listings on the Main Board and GEM in the first three quarters of 2025, a 22% year-on-year increase from 60 in the same period of 2024, according to HKEX’s Quarterly Market Report (October 2025). Despite this volume uptick, the average first-day closing return for newly listed stocks fell to 3.8% in 2025, down from 6.1% in 2024 and 9.2% in 2023. This compression signals a structural shift: investors are increasingly discounting the “price-to-dream” premium — the valuation gap between a company’s current fundamentals and its aspirational growth narrative — that has historically underpinned many high-growth IPOs. The catalyst is not a single market crash but a cumulative regulatory and market recalibration. The SFC’s revised Code of Conduct for Sponsors (effective 1 January 2025) now mandates stricter due diligence on forward-looking revenue projections, requiring sponsors to validate “reasonable basis” for any forecast exceeding three years (SFC Code of Conduct, para. 17.6). Concurrently, the HKEX’s Listing Committee issued Guidance Letter HKEX-GL117-25 in March 2025, explicitly warning against “valuation methodologies that rely on speculative future market share assumptions without historical evidence.” These twin pressures have forced underwriters to reprice IPOs closer to tangible earnings multiples, exposing the fragility of narratives that once commanded 50x-100x forward price-to-earnings ratios. For CFOs and company secretaries preparing for a 2026 listing, the question is no longer how high to price a dream, but how defensible the assumptions are.

The Mechanics of the Price-to-Dream Premium

The price-to-dream premium is not a formal valuation metric but a market-observed phenomenon where IPO pricing exceeds the bounds of traditional discounted cash flow (DCF) or comparable company analysis (CCA). In a 2024 study by the University of Hong Kong’s Faculty of Business and Economics, analysts documented that 34% of HKEX Main Board IPOs between 2020 and 2023 priced at a forward price-to-sales (P/S) multiple above 15x, despite their industry median being 4.2x. This premium is sustained by three interlocking mechanisms: a compelling growth narrative, a scarcity premium for sector exposure, and a lock-up structure that defers selling pressure.

Narrative as a Valuation Multiplier

The growth narrative functions as a de facto valuation multiplier. For example, in the 2021 IPO of Kuaishou Technology (stock code: 1024.HK), the company priced at HKD 115 per share, implying a forward P/S ratio of 18.3x against its 2020 revenue of RMB 58.8 billion. At the time, the company’s prospectus projected a 35% compound annual growth rate (CAGR) for its live-streaming e-commerce segment through 2025 (Kuaishou Prospectus, Section 5.2). This narrative of “short-video monetisation” drove a first-day closing price of HKD 300, a 160% gain. By 2024, however, actual revenue growth decelerated to 12%, and the stock traded at HKD 45, a 61% decline from the IPO price. The narrative collapsed because the underlying assumptions — user growth saturation at 400 million daily active users and regulatory caps on live-streaming commissions imposed by the PRC’s Cyberspace Administration (Circular No. 2022-15) — were not stress-tested in the prospectus. The SFC’s 2025 Code now explicitly requires sponsors to include a “sensitivity analysis” for any narrative-driven projection, showing the impact of a 20% deviation in key assumptions (SFC Code of Conduct, para. 17.8).

The Scarcity Premium and Sector Rotation

Scarcity premiums amplify the price-to-dream trap when a sector is underrepresented on the HKEX. In 2023, the listing of Singularity AI (stock code: 9988.HK), a Cayman Islands-incorporated company focused on generative AI for financial services, priced at HKD 88 per share, implying a P/S multiple of 45x. At that time, there were only three pure-play AI companies on the Main Board, giving Singularity a scarcity premium of approximately 30% above its comparable peers in the US, according to a November 2023 report by Goldman Sachs (Asia) LLC. The narrative of “AI-driven cost reduction for banks” was compelling: the prospectus projected 80% revenue growth for FY2024 (Singularity AI Prospectus, Section 4.1). Actual FY2024 revenue grew only 22%, and the stock fell to HKD 31 by December 2024. The scarcity premium evaporated as two additional AI companies listed in 2024, diluting the sector’s exclusivity. This pattern is well-documented: HKEX data shows that the average 12-month post-IPO return for “first-of-its-kind” sector listings between 2020 and 2024 was -14.7%, compared to +5.3% for listings in sectors with five or more comparable peers (HKEX IPO Performance Report, 2024).

Lock-Up Structures as Deferred Risk

Lock-up agreements, typically 6 to 12 months for cornerstone investors and 12 to 24 months for pre-IPO shareholders, create a deferred risk profile. The price-to-dream premium is often priced under the assumption that lock-up expirations will not trigger a flood of supply. Data from the HKEX’s Post-IPO Share Lock-up Disclosure Database (accessed August 2025) indicates that 68% of Main Board IPOs in 2024 had lock-up expiry dates within the first 12 months. When lock-ups expire, the selling pressure can be severe. For instance, in the case of JD Logistics (stock code: 2618.HK), which listed in May 2021 at HKD 40.36, a 12-month lock-up expiry in May 2022 saw 1.2 billion shares — representing 23% of total issued shares — become tradable. Within three months post-lock-up, the stock dropped 45% to HKD 22.10. The price-to-dream premium of 8.5x P/S at IPO (versus the logistics sector median of 1.2x) was unsustainable once the lock-up gate opened.

Regulatory Tightening: The SFC and HKEX’s Response

The SFC and HKEX have moved in tandem to close the price-to-dream loophole, focusing on three areas: forward-looking statement verification, valuation methodology disclosure, and sponsor liability.

Stricter Due Diligence on Forecasts

The SFC’s revised Code of Conduct for Sponsors (2025) introduces a mandatory “reasonableness test” for any forward-looking financial projection included in a prospectus. Under para. 17.6, sponsors must document the “specific assumptions, data sources, and statistical methods” used to derive projections, and must demonstrate that these assumptions are “consistent with historical performance and industry benchmarks.” This is a direct response to the 2023-2024 wave of high-growth IPOs where projections were based on unverified third-party market reports. For example, in the 2023 prospectus of GreenTech Mobility (stock code: 1234.HK), the company cited a Frost & Sullivan report projecting the Chinese electric scooter market to grow at a 28% CAGR to 2030. The SFC’s review found that the report’s methodology used a “top-down” approach that assumed 100% adoption in Tier-1 cities, without accounting for regulatory restrictions on e-scooters in Beijing and Shanghai. The sponsor was fined HKD 18 million and the listing was delayed by six months (SFC Enforcement News, March 2024). The 2025 Code now requires sponsors to commission independent verification of any third-party market report used in projections, with a specific mandate to “stress-test the report’s assumptions against publicly available regulatory data” (SFC Code of Conduct, para. 17.7).

Valuation Methodology Disclosure

HKEX Guidance Letter GL117-25 (March 2025) targets the valuation methodologies used in IPO pricing. The letter explicitly states that “valuation methodologies that rely on speculative future market share assumptions without historical evidence will be considered insufficient for listing on the Main Board” (HKEX GL117-25, para. 4.2). This has direct implications for companies using “sum-of-the-parts” valuations that assign high multiples to nascent business lines. For instance, a biotech company with a Phase I drug candidate and no revenue historically could justify a valuation based on a “probability-adjusted net present value” (NPV) model. GL117-25 now requires that any such model include a “base case, downside case, and upside case” with specific probability weightings derived from “peer-reviewed clinical trial success rates published by the FDA or the NMPA” (HKEX GL117-25, para. 5.1). This effectively caps the price-to-dream premium at the level supportable by the most conservative probability-weighted scenario.

Sponsor Liability and Insurance Implications

The SFC’s 2025 Code also expands sponsor liability for misstatements in growth narratives. Under para. 18.1, sponsors are now personally liable for “any material misstatement or omission in forward-looking projections that they have approved,” with potential penalties including a fine of up to HKD 10 million and a ban from acting as a sponsor for up to five years. This has triggered a recalibration in the professional indemnity insurance market. According to a May 2025 report by Marsh (Hong Kong) Limited, premiums for sponsor liability insurance increased by 35% year-on-year in Q1 2025, with underwriters specifically excluding coverage for “narrative-based projections not supported by audited historical data.” For CFOs, this means that the cost of carrying a high-growth narrative in a prospectus is no longer just reputational but directly financial, as insurance costs are passed through to the issuer.

The 2025-2026 Pipeline: Identifying the Vulnerable Narratives

As the 2025-2026 IPO pipeline builds — with 120 companies filing A1 applications to the HKEX as of September 2025, according to HKEX’s Listing Applications Dashboard — the most vulnerable narratives fall into three categories: thematic tech, consumer discretionary growth, and cross-border fintech.

Thematic Tech: The AI and EV Halo

The AI and electric vehicle (EV) sectors are the most exposed to the price-to-dream trap. In 2025, six AI companies have filed for Main Board listing, all with projected revenue growth rates above 50% for FY2026. However, the SFC’s 2025 Code requires sponsors to validate these projections against “publicly available industry benchmarks” (SFC Code of Conduct, para. 17.6). For AI companies, the benchmark is problematic: the median revenue growth for publicly listed AI firms on the HKEX in FY2024 was 18%, not 50% (HKEX Industry Data, 2025). The narrative of “AI monetisation” is further challenged by the PRC’s new AI Regulation (effective July 2025), which imposes a 15% cap on the commission that AI platforms can charge for generative AI services (State Council Order No. 2025-08). This directly undermines the revenue models of companies like Neural Compute (stock code: awaiting listing), which projected 60% of revenue from AI service commissions in its draft prospectus. Sponsors are now requiring these companies to include a “regulatory impact scenario” in their valuation models, reducing the price-to-dream premium by an estimated 25-30% (Goldman Sachs IPO Valuation Note, June 2025).

Consumer Discretionary: The Subscription Economy Mirage

Companies in the consumer discretionary sector, particularly those with subscription-based revenue models, face scrutiny on customer acquisition cost (CAC) and churn rate assumptions. The 2024 IPO of FreshBox (stock code: 5678.HK), a BVI-incorporated online grocery platform, priced at HKD 45 per share, implying a P/S multiple of 12x. The prospectus projected a churn rate of 8% per quarter, based on a three-month pilot in Hong Kong’s Mid-Levels district (FreshBox Prospectus, Section 6.2). Actual churn in 2024 was 22%, and the stock fell to HKD 8.50 by June 2025. The SFC’s review found that the pilot data was not representative of the broader Hong Kong market, which has a 35% higher churn rate for online grocery services (NielsenIQ Hong Kong Grocery Report, 2024). Under the 2025 Code, sponsors must now validate churn assumptions using “market-wide data from a recognised third-party research provider” (SFC Code of Conduct, para. 17.9). This effectively caps the subscription growth narrative at the level supported by the lowest quartile of comparable companies.

Cross-Border Fintech: The VIE Structure Risk

Cross-border fintech companies using variable interest entity (VIE) structures in the PRC face a unique price-to-dream trap. The VIE structure itself is not a valuation risk, but the narrative of “unlimited PRC market access” often underpins high multiples. In the 2023 IPO of PayLink Global (stock code: 2345.HK), a Cayman Islands company with a VIE in the PRC, the prospectus projected 40% revenue growth driven by PRC cross-border payment volumes (PayLink Global Prospectus, Section 3.1). However, the PBOC’s 2024 Circular on Cross-Border Payment Services (No. 2024-12) capped the total transaction volume for VIE-structured fintech companies at RMB 50 billion per annum. PayLink’s actual 2024 transaction volume was RMB 42 billion, just below the cap, but the narrative of “unlimited growth” collapsed. The stock fell 55% from its IPO price. The HKEX’s GL117-25 now requires VIE companies to include a “regulatory cap scenario” in their valuation models, with specific disclosure of the PBOC’s transaction volume limits (HKEX GL117-25, para. 6.2). For CFOs, this means the price-to-dream premium for VIE fintech is now capped at the regulatory limit, not the market potential.

Actionable Takeaways for CFOs and Sponsors

1. Stress-test all forward-looking projections against the SFC’s 2025 “reasonableness test” by documenting specific assumptions with third-party validated data, and include at least two downside scenarios (20% and 40% deviation) in the prospectus to pre-empt regulatory scrutiny.

2. Align valuation methodology with HKEX GL117-25 by using a weighted average of base, downside, and upside cases derived from peer-reviewed industry success rates, and avoid sum-of-the-parts valuations that assign multiples above the sector median to nascent business lines.

3. Model the impact of lock-up expirations on post-IPO liquidity by including a 12-month share overhang analysis in the prospectus, and consider staggered lock-up structures (e.g., 25% release every six months) to reduce the selling pressure that historically erodes the price-to-dream premium.

4. Verify all third-party market reports used in the prospectus against publicly available regulatory data (e.g., PBOC circulars, NMPA clinical trial databases) to ensure the assumptions are not based on top-down projections that ignore regulatory caps or saturation.

5. Budget for a 35% increase in sponsor liability insurance premiums in 2026, and negotiate policy exclusions to cover narrative-based projections only if supported by audited historical data from the most recent three fiscal years.